The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL)

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 2, 2012, Pages 185-190

  Dawar, Richa ^a   Hernandez Ilizaliturri, Francisco ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

B cell lymphoma; immunomodulatory drug; lenalidomide; mantle cell lymphoma

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MONOCLONAL ANTIBODY; RITUXIMAB; STEROID;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CELL CYCLE ARREST; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE FUNCTION; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR FLARE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DISEASE MANAGEMENT; HUMANS; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; LYMPHOMA, MANTLE-CELL; RECURRENCE; T-LYMPHOCYTES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84862226405     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.04.005     Document Type: Review

References (31)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics CA-Cancer J Clin 60 5 2010 277 300 Sep-Oct
2. A. Herrmann, E. Hoster, and T. Zwingers Improvement of overall survival in advanced stage mantle cell lymphoma J Clin Oncol 27 4 2009 Feb 1 511 518
3. E.S. Jaffe The 2008 WHO classification of lymphomas: implications for clinical practice and translational research Hematol Am Soc Hematol Educ Program 2009 523 531
4. Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol. Dec 16.
5. F. Bertoni, A. Rinaldi, and E. Zucca Update on the molecular biology of mantle cell lymphoma Hematol Oncol 24 1 2006 Mar 22 27
6. Dreyling M, Hoster E, Bea S, et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma (MCL): minutes of the 9th European MCL Network conference. Leuk lymphoma. Sep;51(9):1612-1622.
7. P. Jares, D. Colomer, and E. Campo Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics Nat Rev Cancer 7 10 2007 Oct 750 762 (Pubitemid 47463673)
8. G. Lenz, M. Dreyling, and W. Hiddemann Mantle cell lymphoma: established therapeutic options and future directions Ann Hematol 83 2 2004 Feb 71 77 (Pubitemid 38159609)
9. D.D. Weisenburger, J.M. Vose, and T.C. Greiner Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group Am J Hematol 64 3 2000 Jul 190 196 (Pubitemid 30409035)
10. M. Ghielmini, and E. Zucca How I treat mantle cell lymphoma Blood 114 8 2009 Aug 20 1469 1476
11. L.G. Corral, P.A. Haslett, and G.W. Muller Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha J Immunol 163 1 1999 Jul 1 380 386 (Pubitemid 29295864)
12. G.W. Muller, R. Chen, and S.Y. Huang Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production Bioorg Med Chem Lett 9 11 1999 Jun 7 1625 1630 (Pubitemid 29274209)
13. R. LeBlanc, T. Hideshima, and L.P. Catley Immunomodulatory drug costimulates T cells via the B7-CD28 pathway Blood 103 5 2004 Mar 1 1787 1790 (Pubitemid 38268973)
14. F.J. Hernandez-Ilizaliturri, N. Reddy, and B. Holkova Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model Clin Cancer Res 11 16 2005 Aug 15 5984 5992 (Pubitemid 41170330)
15. A.K. Gandhi, J. Kang, and S. Naziruddin Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly Leuk Res 30 7 2006 Jul 849 858 (Pubitemid 43816707)
16. N. Reddy, F.J. Hernandez-Ilizaliturri, and G. Deeb Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo Br J Haematol 140 1 2008 Jan 36 45 (Pubitemid 350233246)
17. L. Wu, M. Adams, and T. Carter lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells Clin Cancer Res 14 14 2008 Jul 15 4650 4657
18. L. Escoubet-Lozach, I.L. Lin, and K. Jensen-Pergakes Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism Cancer Res 69 18 2009 Sep 15 7347 7356
19. L. Zhang, Z. Qian, and Z. Cai Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo Am J Hematol 84 9 2009 Sep 553 559
20. A.G. Ramsay, A.J. Clear, and G. Kelly Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy Blood 114 21 2009 Nov 19 4713 4720
21. V. Kotla, S. Goel, and S. Nischal Mechanism of action of lenalidomide in hematological malignancies J Hematol Oncol 2 2009 36
22. P.H. Wiernik, I.S. Lossos, and J.M. Tuscano Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma J Clin Oncol 26 30 2008 Oct 20 4952 4957
23. T.M. Habermann, I.S. Lossos, and G. Justice Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma Br J Haematol 145 3 2009 May 344 349
24. M.S. Czuczman, J.M. Vose, and P.L. Zinzani Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse Large-B-cell lymphoma: results of an international study (NHL-003) ASH Annu Meet Abstr 112 11 November 16, 2008 268
25. P.L. Zinzani, T.E. Witzig, and J.M. Vose Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of an international study (NHL-003) ASH Annu Meet Abstr 112 11 November 16, 2008 262
26. L. Wang, L. Fayad, and F.B. Hagemeister A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma Blood 114 2009 2719 [Abstract]
27. I.F. Khouri, R.M. Saliba, and G.-J. Okoroji Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score Cancer 98 12 2003 Dec 15 2630 2635 (Pubitemid 37509526)
28. J.E. Romaguera, L. Fayad, and M.A. Rodriguez High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine Erratum Appears J Clin Oncol 24 4 2006 Feb 1 724 J Clin Oncol. [Clinical Trial Clinical Trial, Phase II]. 2005 Oct 1;23(28):7013-23
29. Z. Qian, L. Zhang, and Z. Cai Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo Leuk Res 35 3 2011 Mar 380 386 [In Vitro Research Support, Non-U.S. Gov't]
30. Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neoangiogenic biomarkers. Haematologica. Nov 4.
31. M. Jerkeman, A. Kolstad, and A. Laurell Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 Years with mantle cell lymphoma: results from the phase I Portion of the Nordic lymphoma group MCL4 (LENA-BERIT) trial Blood (ASH Annu Meet Abstracts) 118 2011 2700 [Abstract]